REGULATION OF BREAST CANCER CELL CYCLE BY ESTRADIOL

雌二醇对乳腺癌细胞周期的调节

基本信息

项目摘要

Breast Cancer (breast Ca) is a leading cause of death for women in the U.S. and will affect approximately 105 of the present female population. Many studies have demonstrated that 17beta-estradiol (E2) is a critical factor in the genesis of breast Ca and can promote breast Ca cell growth in vivo as well as in vitro in the presence of growth factors. However, the mechanisms underlying regulation of the breast Ca cell cycle by E2 are poorly, if at all, understood. Our recent data suggests that E2 (in the absence of exogenous growth factors) can directly activate cyclin dependent kinase 2 (Cdk2) activity in MCF-7 cells, leading to hyperphosphorylation of retinoblastoma protein (pRb) and induction of S- phase entry. Furthermore, E2 appears to inactivate a Cdk inhibitor (CKI) present in untreated G1 cells. These regulatory effects of E2 in the nanomolar concentration range are inhibited by an excess of steroidal antiestrogen (ICI l82,780). Thus, we hypothesize that E2 directly regulates one or more of the following critical steps in the MCF-7 cell cycle (a) Expression of D cyclin gene(s) and synthesis of D cyclin(s); (b) Activation of Cdk4 kinase activity; (c) Inhibition of a CKI active in G1 phase; and (d) Activation of Cdk2 kinase activity (perhaps via activation of Cdk activating kinase - CAK) leading to pRb hyperphosphorylation and entry into S-phase. We have proposed 3 specific aims to directly test facets of this hypothesis. They are: (1) Studies to investigate whether E2 regulates D- type cyclin synthesis/degradation, in particular that of cyclin D1, and whether Cdk4 kinase activity and/or steady-state protein levels are regulated by E2. (2) We will investigate the possibility that E2 treatment inactivates a Cdk inhibitor present in quiescent MCF-7 cells resulting in Cdk activation and G1 transit. We propose that E2 will be unable to bring about inactivation of putative inhibitors present in ER negative breast Ca cells or other cells lacking ER. (3) Studies under Specific Aim 3 will explore the possibility that E2, directly or indirectly, regulates cyclin D1 promoter activity. Cyclin D1 promoter reporter gene constructs will be expressed in MCF-7 cells and ER negative breast Ca cells. Specific activation of these promoter constructs in response to E2 will be measured, and specific response elements required for this activation will be determined by deletion and mutation experiments. The results of these studies will, for the first time, directly demonstrate how E2 regulates early events in the cell cycle of E2 responsive breast Ca cells.
乳腺癌(Breast Ca)是美国妇女死亡的主要原因

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Removal of Cdk inhibitors through both sequestration and downregulation in zearalenone-treated MCF-7 breast cancer cells.
通过玉米赤霉烯酮处理的 MCF-7 乳腺癌细胞中的隔离和下调来去除 Cdk 抑制剂。
  • DOI:
    10.1002/mc.10048
  • 发表时间:
    2002
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Ahamed,Shamila;Foster,JamesS;Bukovsky,Antonin;Diehl,JAlan;Wimalasena,Jay
  • 通讯作者:
    Wimalasena,Jay
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JAY wimalasena WIMALASENA其他文献

JAY wimalasena WIMALASENA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JAY wimalasena WIMALASENA', 18)}}的其他基金

APOPTOSIS & CELL CYCLE IN BREAST & OVARIAN CANCER CELLS
细胞凋亡
  • 批准号:
    6342200
  • 财政年份:
    2000
  • 资助金额:
    $ 18.84万
  • 项目类别:
APOPTOSIS & CELL CYCLE IN BREAST & OVARIAN CANCER CELLS
细胞凋亡
  • 批准号:
    6032882
  • 财政年份:
    2000
  • 资助金额:
    $ 18.84万
  • 项目类别:
APOPTOSIS & CELL CYCLE IN BREAST & OVARIAN CANCER CELLS
细胞凋亡
  • 批准号:
    6489338
  • 财政年份:
    2000
  • 资助金额:
    $ 18.84万
  • 项目类别:
APOPTOSIS & CELL CYCLE IN BREAST & OVARIAN CANCER CELLS
细胞凋亡
  • 批准号:
    6626727
  • 财政年份:
    2000
  • 资助金额:
    $ 18.84万
  • 项目类别:
REGULATION OF BREAST CANCER CELL CYCLE BY ESTRADIOL
雌二醇对乳腺癌细胞周期的调节
  • 批准号:
    2429869
  • 财政年份:
    1996
  • 资助金额:
    $ 18.84万
  • 项目类别:
REGULATION OF BREAST CANCER CELL CYCLE BY ESTRADIOL
雌二醇对乳腺癌细胞周期的调节
  • 批准号:
    2112531
  • 财政年份:
    1996
  • 资助金额:
    $ 18.84万
  • 项目类别:
EFFECTS OF ALCOHOL ON HUMAN OVARIAN CELL FUNCTION
酒精对人类卵巢细胞功能的影响
  • 批准号:
    3112386
  • 财政年份:
    1992
  • 资助金额:
    $ 18.84万
  • 项目类别:
EFFECTS OF ALCOHOL ON HUMAN OVARIAN CELL FUNCTION
酒精对人类卵巢细胞功能的影响
  • 批准号:
    2044423
  • 财政年份:
    1992
  • 资助金额:
    $ 18.84万
  • 项目类别:
ALCOHOL EFFECTS ON OVARIAN CELL FUNCTION
酒精对卵巢细胞功能的影响
  • 批准号:
    2044425
  • 财政年份:
    1992
  • 资助金额:
    $ 18.84万
  • 项目类别:
ROLE OF GONADOTROPINS IN OVARIAN CANCER
促性腺激素在卵巢癌中的作用
  • 批准号:
    3509585
  • 财政年份:
    1991
  • 资助金额:
    $ 18.84万
  • 项目类别:

相似海外基金

NOVEL RNASE PROTECTION ASSAY FOR CYTOKINE MRNAS
细胞因子 MRNAS 的新型 RNA 酶保护测定
  • 批准号:
    6317727
  • 财政年份:
    2000
  • 资助金额:
    $ 18.84万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了